{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:17:08Z","timestamp":1788304628366,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.hlc.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:54:02Z","timestamp":1788303242000},"page":"1187-1189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Lp(a) Revolution in Dyslipidaemia Management, From Obscurity to Class 1 Recommendation: Aligning Australian Practice With Global Guidelines"],"prefix":"10.1016","volume":"35","author":[{"given":"David L.","family":"Hare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2026.08.001_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.hlc.2025.11.017","article-title":"Prevalence of lipoprotein(a) testing in patients with atherosclerotic cardiovascular disease within a large Australian cardiology network","volume":"35","author":"Eccleston","year":"2026","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2026.08.001_bib2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.hlc.2026.01.007","article-title":"10-year trends in lipoprotein(a) testing in Queensland and Australia: a retrospective analysis of ordering patterns","volume":"35","author":"Bachmeier","year":"2026","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2026.08.001_bib3","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler. Thromb Vasc Biol"},{"key":"10.1016\/j.hlc.2026.08.001_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the Lp system","volume":"5","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.hlc.2026.08.001_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-0004.1974.tb00657.x","article-title":"Lp(a) lipoprotein and pre-\u03b21-lipoprotein in patients with coronary heart disease","volume":"6","author":"Berg","year":"1974","journal-title":"Clin Genet"},{"key":"10.1016\/j.hlc.2026.08.001_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2026.08.001_bib7","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2026.08.001_bib8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2026.08.001_bib9","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2026.08.001_bib10","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.hlc.2026.08.001_bib11","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2026.08.001_bib12","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.hlc.2020.03.005","article-title":"The prevalence of elevated lipoprotein(a) in patients presenting with coronary artery disease","volume":"29","author":"Oo","year":"2020","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2026.08.001_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hlc.2022.11.015","article-title":"Australian Atherosclerosis Society Position Statement on lipoprotein(a): clinical and implementation recommendations","volume":"32","author":"Ward","year":"2023","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2026.08.001_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2026.08.001_bib15","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2026.08.001_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/eurheartj\/ehaf919","article-title":"The '10 commandments' for the 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"47","author":"Mach","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2026.08.001_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062601694X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062601694X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:54:07Z","timestamp":1788303247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S144395062601694X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S144395062601694X"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2026.08.001","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Lp(a) Revolution in Dyslipidaemia Management, From Obscurity to Class 1 Recommendation: Aligning Australian Practice With Global Guidelines","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2026.01.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.11.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}